A DEA administrative law judge has denied MedPharm's motion to participate in the December 2 marijuana rescheduling hearing, deferring to DEA Administrator Anne Milgram's authority. MedPharm, a ...
But cannabis-reform advocates this week asked a judge to remove the DEA from its own hearing, arguing the agency has ...
A researcher has filed a lawsuit against the Drug Enforcement Administration, accusing the agency of multiple legal ...
DEA and anti-cannabis group must respond to allegations of unlawful talks by November 25. Legal tensions rise ahead of ...
The DEA could allow more participants to testify at upcoming hearings concerning marijuana rescheduling in addition to the ...
By Terry Hacienda, The Fresh Toast It has been clear the DEA It has been clear Anne Milgram, the head of the D ...
The group sees Schedule III as "inadequate" for veterans' needs. But the DEA excluded it from the witness list, and a judge ...
The cannabis industry is concerned about the direction of regulations – and the DEA is still against the plant.
Schedule III drugs, as defined by the DEA, are "drugs with a moderate to low potential for physical and psychological ...
Filing asserts that the DEA failed to maintain a complete record and ensure fairness and transparency – – Filing also asserts DEA is compromised and should be barred from participation in these ...
The rulemaking process that could lead to reclassifying marijuana is lengthy and includes a hearing in DEA administrative court. It is expected to happen in January or February, according to an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback